VBIV Stock Overview
VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
VBI Vaccines Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.60 |
| 52 Week High | US$3.47 |
| 52 Week Low | US$0.45 |
| Beta | 1.92 |
| 1 Month Change | 3.34% |
| 3 Month Change | -6.05% |
| 1 Year Change | -75.93% |
| 3 Year Change | -99.38% |
| 5 Year Change | -98.95% |
| Change since IPO | -99.89% |
Recent News & Updates
Recent updates
VBI Vaccines: Recent Updates Have Fortified My Long-Term Outlook
Sep 22VBI Vaccines gets up to $100M debt funding from K2 HealthVentures
Sep 15Valneva, VBI Vaccines in pact to launch Hep B vaccine in Europe
Sep 08VBI Vaccines down 10% on $300M mixed shelf offering; also ends two equity offerings
Aug 26VBI Vaccines: Recent VBI-1901 Data Supports My Bull Thesis
Jun 17Is VBI Vaccines (NASDAQ:VBIV) A Risky Investment?
Jun 09
Is VBI Vaccines (NASDAQ:VBIV) Using Debt Sensibly?
Jan 24VBI Vaccines: Hepatitis Vaccine Approval Can Be A Catalyst For >$1bn Valuation
Oct 31Is VBI Vaccines (NASDAQ:VBIV) Weighed On By Its Debt Load?
Oct 06VBI Vaccines: Turning My Focus To VBI-1901
Jul 15VBI Vaccines (NASDAQ:VBIV) Has Debt But No Earnings; Should You Worry?
Jul 08Shareholder Returns
| VBIV | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.8% | 0.4% | 1.0% |
| 1Y | -75.9% | 0.9% | 21.9% |
Return vs Industry: VBIV underperformed the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: VBIV underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| VBIV volatility | |
|---|---|
| VBIV Average Weekly Movement | 15.2% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VBIV's share price has been volatile over the past 3 months.
Volatility Over Time: VBIV's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 135 | Jeff Baxter | www.vbivaccines.com |
VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.
VBI Vaccines Inc. Fundamentals Summary
| VBIV fundamental statistics | |
|---|---|
| Market cap | US$17.04m |
| Earnings (TTM) | -US$93.84m |
| Revenue (TTM) | US$8.68m |
2.0x
P/S Ratio-0.2x
P/E RatioIs VBIV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VBIV income statement (TTM) | |
|---|---|
| Revenue | US$8.68m |
| Cost of Revenue | US$12.51m |
| Gross Profit | -US$3.82m |
| Other Expenses | US$90.02m |
| Earnings | -US$93.84m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.30 |
| Gross Margin | -44.06% |
| Net Profit Margin | -1,080.87% |
| Debt/Equity Ratio | 674.5% |
How did VBIV perform over the long term?
See historical performance and comparison